<p>根据 Benzinga 的报道，Bank of America 的股票研究分析师在周一发布的报告中，将 Vertex Pharmaceuticals（纳斯达克代码：VRTX）的目标价格从 555.00 美元上调至 567.00 美元。该券商目前对这家制药公司的股票给予 “买入” 评级。Bank of America 的目标价格意味着该股票相较于之前的收盘价有 15.08% 的潜在上涨空间。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>其他一些股票研究分析师最近也对 VRTX 发布了报告。Cantor Fitzgerald 在 2 月 11 日的研究报告中重申了对 Vertex Pharmaceuticals 的 “增持” 评级，并给出了 480.00 美元的目标价格。巴克莱将 Vertex Pharmaceuticals 的目标价格从 435.00 美元上调至 467.00 美元，并在 2 月 11 日的报告中给予该股票 “持平” 评级。Piper Sandler 在 1 月 27 日的研究报告中将 Vertex Pharmaceuticals 的目标价格从 535.00 美元下调至 533.00 美元，并对该公司给予 “增持” 评级。Truist Financial 在 2 月 11 日的报告中将 Vertex Pharmaceuticals 的目标价格从 460.00 美元上调至 520.00 美元，并给予该公司 “买入” 评级。最后，富国银行在 1 月 30 日的报告中将 Vertex Pharmaceuticals 的评级从 “增持” 下调至 “持平”，并设定了 460.00 美元的目标价格。十位投资分析师对该股票给予了持有评级，十六位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 508.65 美元。</p>
<p><strong>查看我们最新的 VRTX 股票报告</strong></p>
<h2>Vertex Pharmaceuticals 股票表现</h2>
<ul>
<li>Vertex 的止痛药：大型制药公司的下一个重大成功？</li>
</ul>
<p>VRTX 的股票在周一以 492.69 美元开盘。该公司的 50 日移动平均线为 476.45 美元，200 日移动平均线为 463.64 美元。公司的市值为 1265.2 亿美元，市盈率为-223.95，市盈增长比率为 2.11，贝塔值为 0.41。公司的债务股本比率为 0.01，流动比率为 2.69，速动比率为 2.35。Vertex Pharmaceuticals 的年低为 377.85 美元，年高为 519.88 美元。</p>
<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX）最近在 2 月 10 日发布了季度财报。该制药公司报告的每股收益为 3.54 美元，低于分析师一致预期的 3.99 美元，差距为 0.45 美元。Vertex Pharmaceuticals 的股本回报率为-2.02%，净利润率为-4.86%。整体来看，股票分析师预测 Vertex Pharmaceuticals 在本年度的每股收益将达到 15.63 美元。</p>
<h2>内部买卖情况</h2>
<ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
<p>在其他 Vertex Pharmaceuticals 的新闻中，执行副总裁 Ourania Tatsis 在 2 月 18 日的交易中出售了 244 股公司的股票。该股票以 455.06 美元的平均价格出售，总价值为 111,034.64 美元。交易后，该执行副总裁现在直接持有 67,695 股公司的股票，价值约为 30,805,286.70 美元。此次交易使其持股减少了 0.36%。该出售在向证券交易委员会的备案中披露，可以通过此链接访问。此外，执行副总裁 David Altshuler 在 3 月 10 日的交易中出售了 3,231 股公司的股票。该股票以 500.00 美元的平均价格出售，总交易额为 1,615,500.00 美元。出售后，该执行副总裁现在直接持有 26,512 股公司的股票，价值约为 13,256,000 美元。此次交易使其持股减少了 10.86%。该出售的披露信息可以在此找到。内部人士在上个季度出售了 4,315 股公司股票，价值为 2,121,012 美元。内部人士持有公司股票的比例为 0.20%。</p>
<h2>对 Vertex Pharmaceuticals 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近对 VRTX 的持仓进行了调整。公共部门养老金投资委员会在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 14.2%。公共部门养老金投资委员会现在持有 11,244 股该制药公司的股票，价值为 5,229,000 美元，在此期间又增持了 1,400 股。Captrust Financial Advisors 在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 2.2%。Captrust Financial Advisors 现在持有 14,409 股该制药公司的股票，价值为 6,701,000 美元，在此期间又增持了 307 股。Kestra Investment Management LLC 在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 28.7%。Kestra Investment Management LLC 现在持有 2,315 股该制药公司的股票，价值为 1,077,000 美元，在上个季度又增持了 516 股。Benjamin Edwards Inc.在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 4,913.5%。Benjamin Edwards Inc.现在持有 6,668 股该制药公司的股票，价值为 3,101,000 美元，在上个季度又增持了 6,535 股。最后，Beck Capital Management LLC 在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Beck Capital Management LLC 现在持有 2,004 股该制药公司的股票，价值为 932,000 美元，在上个季度又增持了 38 股。机构投资者持有公司股票的比例为 90.96%。</p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变、年龄在 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为年龄在 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO，适用于 ivacaftor 治疗。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Vertex Pharmaceuticals 更具吸引力</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>Lululemon 回调至经典的买入机会</li>
<li>初学者如何阅读股票图表</li>
<li>Cintas 发布盈利超预期，预示未来增长</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>分析师表示这四只低市盈率消费周期股值得买入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>美国银行已将 Vertex Pharmaceuticals（纳斯达克代码：VRTX）的目标股价从 555.00 美元上调至 567.00 美元，维持 “买入” 评级。这个新目标暗示该股票相较于前一交易日收盘价有 15.08% 的潜在上涨空间。其他分析师也调整了他们的评级，普遍评级为 “适度买入”，平均目标股价为 508.65 美元。Vertex 的股票开盘价为 492.69 美元，市值为 1265.2 亿美元。该公司报告上个季度每股收益为 3.54 美元，低于预期 0.45 美元</p>

<p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price objective boosted by equities research analysts at Bank of America from $555.00 to $567.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the pharmaceutical company's stock. Bank of America's price objective would indicate a potential upside of 15.08% from the stock's previous close.</p>
<div class="lb-trans"><p>根据 Benzinga 的报道，Bank of America 的股票研究分析师在周一发布的报告中，将 Vertex Pharmaceuticals（纳斯达克代码：VRTX）的目标价格从 555.00 美元上调至 567.00 美元。该券商目前对这家制药公司的股票给予 “买入” 评级。Bank of America 的目标价格意味着该股票相较于之前的收盘价有 15.08% 的潜在上涨空间。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>A number of other equities research analysts have also recently issued reports on VRTX. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Barclays upped their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an &#34;equal weight&#34; rating in a report on Tuesday, February 11th. Piper Sandler lowered their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, January 27th. Truist Financial raised their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, February 11th. Finally, Wells Fargo &amp; Company cut Vertex Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $508.65.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对 VRTX 发布了报告。Cantor Fitzgerald 在 2 月 11 日的研究报告中重申了对 Vertex Pharmaceuticals 的 “增持” 评级，并给出了 480.00 美元的目标价格。巴克莱将 Vertex Pharmaceuticals 的目标价格从 435.00 美元上调至 467.00 美元，并在 2 月 11 日的报告中给予该股票 “持平” 评级。Piper Sandler 在 1 月 27 日的研究报告中将 Vertex Pharmaceuticals 的目标价格从 535.00 美元下调至 533.00 美元，并对该公司给予 “增持” 评级。Truist Financial 在 2 月 11 日的报告中将 Vertex Pharmaceuticals 的目标价格从 460.00 美元上调至 520.00 美元，并给予该公司 “买入” 评级。最后，富国银行在 1 月 30 日的报告中将 Vertex Pharmaceuticals 的评级从 “增持” 下调至 “持平”，并设定了 460.00 美元的目标价格。十位投资分析师对该股票给予了持有评级，十六位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 508.65 美元。</p>
</div><p><strong>View Our Latest Stock Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 VRTX 股票报告</strong></p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表现</h2>
</div><ul>
<li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex 的止痛药：大型制药公司的下一个重大成功？</li>
</ul>
</div><p>Shares of VRTX opened at $492.69 on Monday. The firm has a 50-day moving average of $476.45 and a 200-day moving average of $463.64. The company has a market cap of $126.52 billion, a PE ratio of -223.95, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.</p>
<div class="lb-trans"><p>VRTX 的股票在周一以 492.69 美元开盘。该公司的 50 日移动平均线为 476.45 美元，200 日移动平均线为 463.64 美元。公司的市值为 1265.2 亿美元，市盈率为-223.95，市盈增长比率为 2.11，贝塔值为 0.41。公司的债务股本比率为 0.01，流动比率为 2.69，速动比率为 2.35。Vertex Pharmaceuticals 的年低为 377.85 美元，年高为 519.88 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, equities analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX）最近在 2 月 10 日发布了季度财报。该制药公司报告的每股收益为 3.54 美元，低于分析师一致预期的 3.99 美元，差距为 0.45 美元。Vertex Pharmaceuticals 的股本回报率为-2.02%，净利润率为-4.86%。整体来看，股票分析师预测 Vertex Pharmaceuticals 在本年度的每股收益将达到 15.63 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
</div><p>In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock valued at $2,121,012 over the last quarter. Insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新闻中，执行副总裁 Ourania Tatsis 在 2 月 18 日的交易中出售了 244 股公司的股票。该股票以 455.06 美元的平均价格出售，总价值为 111,034.64 美元。交易后，该执行副总裁现在直接持有 67,695 股公司的股票，价值约为 30,805,286.70 美元。此次交易使其持股减少了 0.36%。该出售在向证券交易委员会的备案中披露，可以通过此链接访问。此外，执行副总裁 David Altshuler 在 3 月 10 日的交易中出售了 3,231 股公司的股票。该股票以 500.00 美元的平均价格出售，总交易额为 1,615,500.00 美元。出售后，该执行副总裁现在直接持有 26,512 股公司的股票，价值约为 13,256,000 美元。此次交易使其持股减少了 10.86%。该出售的披露信息可以在此找到。内部人士在上个季度出售了 4,315 股公司股票，价值为 2,121,012 美元。内部人士持有公司股票的比例为 0.20%。</p>
</div><h2>Hedge Funds Weigh In On Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Vertex Pharmaceuticals 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in VRTX. Public Sector Pension Investment Board grew its stake in Vertex Pharmaceuticals by 14.2% in the third quarter. Public Sector Pension Investment Board now owns 11,244 shares of the pharmaceutical company's stock valued at $5,229,000 after acquiring an additional 1,400 shares during the period. Captrust Financial Advisors grew its position in Vertex Pharmaceuticals by 2.2% in the 3rd quarter. Captrust Financial Advisors now owns 14,409 shares of the pharmaceutical company's stock valued at $6,701,000 after purchasing an additional 307 shares during the period. Kestra Investment Management LLC increased its stake in Vertex Pharmaceuticals by 28.7% during the 3rd quarter. Kestra Investment Management LLC now owns 2,315 shares of the pharmaceutical company's stock valued at $1,077,000 after purchasing an additional 516 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in Vertex Pharmaceuticals by 4,913.5% during the third quarter. Benjamin Edwards Inc. now owns 6,668 shares of the pharmaceutical company's stock worth $3,101,000 after buying an additional 6,535 shares during the last quarter. Finally, Beck Capital Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.9% in the third quarter. Beck Capital Management LLC now owns 2,004 shares of the pharmaceutical company's stock valued at $932,000 after buying an additional 38 shares in the last quarter. Institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对 VRTX 的持仓进行了调整。公共部门养老金投资委员会在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 14.2%。公共部门养老金投资委员会现在持有 11,244 股该制药公司的股票，价值为 5,229,000 美元，在此期间又增持了 1,400 股。Captrust Financial Advisors 在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 2.2%。Captrust Financial Advisors 现在持有 14,409 股该制药公司的股票，价值为 6,701,000 美元，在此期间又增持了 307 股。Kestra Investment Management LLC 在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 28.7%。Kestra Investment Management LLC 现在持有 2,315 股该制药公司的股票，价值为 1,077,000 美元，在上个季度又增持了 516 股。Benjamin Edwards Inc.在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 4,913.5%。Benjamin Edwards Inc.现在持有 6,668 股该制药公司的股票，价值为 3,101,000 美元，在上个季度又增持了 6,535 股。最后，Beck Capital Management LLC 在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Beck Capital Management LLC 现在持有 2,004 股该制药公司的股票，价值为 932,000 美元，在上个季度又增持了 38 股。机构投资者持有公司股票的比例为 90.96%。</p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变、年龄在 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为年龄在 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO，适用于 ivacaftor 治疗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Lululemon Pulls Back Into Classic Dip-Buying Opportunity</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Cintas Delivers Earnings Beat, Signals More Growth Ahead</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Analysts Say These 4 Low P/E Consumer Cyclical Stocks Are Buys</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Vertex Pharmaceuticals 更具吸引力</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>Lululemon 回调至经典的买入机会</li>
<li>初学者如何阅读股票图表</li>
<li>Cintas 发布盈利超预期，预示未来增长</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>分析师表示这四只低市盈率消费周期股值得买入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

美国银行将福泰制药（NASDAQ:VRTX）的目标价上调至 567.00 美元